FGLL
Alternative Names: Neural cell adhesion molecule mimeticLatest Information Update: 13 Dec 2011
At a glance
- Originator ENKAM Pharmaceuticals A/S
- Class Antidementias; Neuroprotectants; Nootropics; Peptides
- Mechanism of Action Fibroblast growth factor receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes
Highest Development Phases
- Discontinued Alzheimer's disease
Most Recent Events
- 12 Dec 2011 Discontinued - Phase-I for Alzheimer's disease in European Union (Intranasal)
- 12 Dec 2011 Discontinued - Phase-I for Alzheimer's disease in Switzerland (Intranasal)
- 30 Dec 2009 FGLL is available for licensing as of 30 Dec 2009. http://www.enkam.com